• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Research Brief on H-Tle-OH.HCl (CAS: 139163-43-2) in Chemical Biology and Pharmaceutical Applications

H-Tle-OH.HCl (CAS: 139163-43-2), a hydrochloride salt of L-tert-leucine, has garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and versatile applications. This non-proteinogenic amino acid derivative serves as a critical building block in peptide synthesis, chiral auxiliaries, and drug design. Recent studies highlight its role in improving metabolic stability, enhancing bioavailability, and modulating the physicochemical properties of therapeutic peptides and small molecules.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of H-Tle-OH.HCl in stabilizing β-turn structures in cyclic peptides targeting GPCRs, with a 40% increase in plasma half-life compared to linear analogs. The steric hindrance introduced by the tert-butyl group was shown to reduce enzymatic degradation while maintaining target affinity. Parallel research in ACS Chemical Biology revealed its effectiveness as a chiral resolving agent for racemic mixtures in asymmetric synthesis, achieving >99% ee for several kinase inhibitors under optimized conditions.

Industrial applications have expanded significantly, with H-Tle-OH.HCl being incorporated into GMP manufacturing processes for novel antidiabetic peptides (Phase II clinical trials) and next-generation HCV protease inhibitors. Analytical characterization studies using HPLC-MS (Waters Corp, 2024) established robust purity standards (>99.5%) and identified key degradation pathways under accelerated stability conditions. The compound's safety profile was recently re-evaluated in a Regulatory Toxicology and Pharmacology meta-analysis, confirming Class 3 LD50 (>2000 mg/kg) with no genotoxic alerts across five assay systems.

Emerging applications include its use as a template for metal-organic frameworks (MOFs) in drug delivery systems, as reported in Advanced Materials (2024). The tert-leucine moiety facilitated precise pore size control (2.1-3.4 nm) while maintaining biocompatibility. Computational modeling studies (JChem, 2023) have further elucidated its conformational preferences in aqueous versus organic media, providing valuable insights for formulation scientists.

Supply chain analyses indicate growing demand, with global production capacity increasing by 35% year-over-year (Chemical Market Analytics, Q1 2024). Regulatory filings show 17 new drug applications incorporating H-Tle-OH.HCl derivatives in the past 18 months, predominantly in oncology (45%) and metabolic diseases (30%). Continuous flow synthesis methods developed by MIT researchers (2023) have reduced production costs by 60% while improving E-factor metrics to <3, addressing previous scalability challenges.

Future research directions focus on three key areas: 1) Development of novel protecting group strategies for selective modification, 2) Exploration of its role in stabilizing α-helical peptide therapeutics, and 3) Investigation of its potential as a cryoprotectant in biopharmaceutical formulations. The compound's unique combination of steric bulk and chemical stability positions it as a versatile tool for next-generation drug discovery and development.

• 33105-81-6(2-Amino-3,3-dimethylbutanoic acid)
• 112720-39-5((R)-2-Amino-3,3-dimethylbutanoic acid hydrochloride)
• 35045-72-8(L-Valine-d)
• 17498-50-9(L-ValineHydrochloride)
• 20859-02-3((S)-2-amino-3,3-dimethylbutanoic acid)
• 59935-29-4(L-Valine-15N)
• 77257-03-5(L-Valine-2-d1)
• 26782-71-8(D-a-tert-Butyl-Gly-OH)
• 64442-11-1(Lysine, 5,5-dimethyl-, monohydrochloride)
• 71261-62-6(Valine-15N (9CI))